A lesson for everyone in drug-drug interactions

International Journal of Cardiology

Volumn 118, Issue 1, 2007, Pages

  Akram, Kamran ^a   Rao, Swapna ^b   Parker, Miriam ^a  

^a ATLANTA MEDICAL CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Ketoconazole; Rhabdomyolysis; Simvastatin

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; CYCLOBENZAPRINE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARACETAMOL; PHOSPHORUS; SIMVASTATIN; TROPONIN I; UREA;

ADVERSE OUTCOME; AGED; AGING; ARTICLE; CASE REPORT; CLINICAL PRACTICE; COMORBIDITY; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RHABDOMYOLYSIS;

AGED, 80 AND OVER; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KETOCONAZOLE; MALE; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 34047126299     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.11.235     Document Type: Article

References (4)

1. Harris K.A., Weinberg V., Bok R.A., Kakefuda M., and Small E.J. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168 (2002) 542-545
2. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147 (2004) 956-965
3. Dresser G.K., Spence J.D., and Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38 (2000) 41-57
4. Itakura H., Vaughn D., Haller D.G., and O'Dwyer P.J. Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer. J Urol 169 (2003) 613